DHX58 and cancer: Although there are still few studies on the DHX58 role in tumors, RIG-1 signaling pathway activation, which results in the stimulation of cytotoxic immune cells 37, 38, showed prospects for development in cancer immunotherapy when combined with immune checkpoint inhibitors in clinical trials.